Skip to main content

Displaying 3041 - 3060 of 4793

Actavis, Inc. and Warner Chilcott PLC, In the Matter of

Under a settlement, the FTC required Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.The settlement protects competition in the markets for 21 current and future generic drugs, used to treat a wide range of conditions ranging from hypertension and diabetes to anxiety and attention deficit hyperactivity disorder (ADHD).

Type of Action
Administrative
Last Updated
FTC Matter/File Number
131 0152
Docket Number
C-4414

FTC Launches Redesigned FTC.gov Website

Date
The Federal Trade Commission today launched a redesigned FTC.gov website that’s easier to use and reader friendly on tablets and smart phones. Users can now sort FTC cases, early termination notices...